The most common reason GH peptides underperform has nothing to do with the compound. It is when the injection is happening.
Most researchers inject GH secretagogues like Tesamorelin and CJC-1295 at bedtime because sleep is when growth hormone is released. A secretagogue is just a compound that signals the body to put out its own growth hormone rather than adding hormone from outside. The logic sounds right. The data does not support it for most compounds. Understanding why changes how the entire protocol performs, without changing the dose, the compound, or the cost.
This guide covers the timing error that research suggests accounts for more lost output than wrong compound selection. One thing to keep in mind throughout: most of this rests on how growth hormone behaves in human physiology studies and on practical protocol experience rather than on large trials of each of these specific compounds, so treat it as well reasoned rather than fully settled.
Researchers who have been running Tesamorelin, CJC-1295, or Ipamorelin at bedtime for weeks or months and are not seeing the output they expected.
Anyone whose GH stack results are inconsistent or weaker than the research suggests they should be, and who has not yet examined injection timing as the variable.
Researchers running a GH secretagogue alongside a GLP-1 compound, where the standard fasted window may no longer be sufficient.
The Bedtime Default Error
The logic behind bedtime injection is reasonable on the surface. Growth hormone peaks during deep sleep, roughly 60 to 90 minutes after falling asleep. So injecting at bedtime should align with that peak. The problem is that Tesamorelin has an active window of approximately 2 to 3 hours. If you inject at 10pm, the compound signal is fading by midnight, well before most people hit their deepest GH producing sleep.
Daytime injection creates a pulse your body does not naturally produce at that time of day. That is the key distinction, and the mechanism points to it being an addition to total GH output, not a replacement of the natural pulse. The natural bedtime peak still happens. You now have two windows of elevated GH output instead of one poorly timed window.
In practice, more protocol progress tends to be lost to timing errors than to wrong compound selection. A researcher can have the right compound at the right dose and still get a fraction of the output because the injection window is working against the body's natural signaling pattern.
The One Bedtime Exception: CJC-1295 Without DAC
CJC-1295 without DAC has a shorter active window than Tesamorelin. DAC is a modifier that stretches how long the compound stays active, so the version without it clears the body faster. When injected at bedtime, research suggests the pulse completes well before the natural GH peak occurs during deep sleep. Because the pulse finishes early, the natural peak arrives intact and is not disrupted. The compound adds its signal, clears, and the body's own pulse runs on schedule.
This makes CJC-1295 without DAC the one GH secretagogue where bedtime injection is a rational timing choice based on the research, though that comparison rests more on practical protocol experience than on large head to head human studies. Every other common secretagogue, Tesamorelin in particular, follows the daytime fasted rule. Applying bedtime logic to Tesamorelin because CJC works that way is the error most researchers make when switching between the two. Sermorelin sits in this same family of growth hormone releasing compounds, and researchers often weigh it against Tesamorelin when picking a base, so if you are choosing between them the practical differences are laid out in this breakdown of sermorelin vs tesamorelin.
The correct timing window depends on the compound's active duration relative to when the natural GH peak occurs during sleep. This table covers the most common GH secretagogues.
| Compound | Optimal timing | Bedtime rational? |
|---|---|---|
| Tesamorelin | Fasted daytime, morning or early afternoon. Pulse completes during active hours, adding output without displacing the natural peak. | No Active window too short. Signal fades before deep sleep GH window. |
| CJC-1295 (no DAC) | Bedtime is the rational choice. Pulse completes before natural peak. Natural pulse arrives intact. | Yes Shorter window means it clears before the deep sleep peak. |
| Ipamorelin | Fasted. Always paired with a GHRH compound (Tesamorelin or CJC), injected 15 to 30 minutes after. Active window approximately 2 hours. | Depends Rational only if paired with CJC at bedtime. Not if running Tesamorelin. |
| GHRP-6 | Fasted, 2 to 3 times daily. Significant appetite signal expected post-injection because it switches on the ghrelin pathway, the body's hunger signal. | Not recommended Strong hunger signal disrupts sleep quality. |
The Protocol Intelligence Tool maps every compound in your stack to its receptor targets and flags where two compounds are driving the same binding site. For this combination it identifies the shared pathways and shows exactly where the signals converge. That picture is what the receptor map requires before any stacking decision can be evaluated accurately.
Run the Protocol Intelligence ToolWhy the Fasted Window Is the Primary Variable
The rule is simple: insulin present at injection time blunts the GH pulse. Any meal within 2 to 3 hours of injection, especially one with carbohydrates or protein, raises insulin and reduces the secretagogue response significantly. This is not a minor optimization. Research suggests it is the primary variable that determines whether the compound produces its documented effect or a fraction of it.
Researchers who inject consistently without fasting still see results from GH secretagogues. The data supports that. But the output is not optimized. If the goal is to get the full signal the compound is designed to produce, the fasted window is not optional.
The post-injection window matters as well. Waiting 60 to 90 minutes after injection before eating gives the GH pulse time to complete before food intake triggers somatostatin, the signal that stops GH release. Eating too soon after injection cuts the pulse short.
The GLP-1 Problem: Why Your Fasted Window Is Probably Too Short
GLP-1 compounds slow gastric emptying, which just means they slow how fast food leaves the stomach. Food that would normally clear in 3 to 4 hours may take 5 to 7 hours on an active GLP-1 protocol. Those hour figures are rough estimates, not fixed numbers, and for a long acting GLP-1 the slowdown often eases over the first weeks or months as the body adjusts to it. Still, the standard 2 to 3 hour post-meal fast a researcher has been using for months is no longer a confirmed fasted state once a GLP-1 compound is added, at least not early on.
Research suggests extending the fasted window to 4 to 5 hours post-meal when running a GLP-1 compound alongside GH secretagogues. If the GH pulse appears weaker than expected after adding a GLP-1 compound, extending the fasted window is the first variable to check before assuming a dosing problem.
Researchers who inject GH secretagogues using a standard 2 to 3 hour post-meal fast on an active GLP-1 protocol may still have food in the stomach, and insulin still active, because gastric emptying has slowed. The fix is not a higher dose. It is a longer fast.
How to Sequence Tesamorelin and Ipamorelin in the Same Window
When running both a GHRH compound (a growth hormone releasing signal, like Tesamorelin or CJC-1295) and a GHRP compound (a pulse amplifier, like Ipamorelin) together, the sequence within the injection window matters. Tesamorelin loads the pituitary, the gland that releases growth hormone, by signaling it to prepare for GH release. Ipamorelin then fires the amplified pulse. Injecting them simultaneously is common but misses the priming window.
Research suggests injecting the GHRH compound first, then Ipamorelin 15 to 30 minutes later while the priming signal is still active. The pituitary is loaded and ready when the Ipamorelin pulse fires. The combined signal is larger than either compound produces alone. This sequencing principle is the same whether the GHRH compound is Tesamorelin or CJC-1295.
The free protocol check maps your current compounds to the bottleneck they were built to solve. If the bottleneck has already been addressed, it flags it. Before adding a second compound, knowing which variable is actually limiting the result is the more useful starting point than assuming more is better.
Run the Free Protocol CheckThe Three Timing Fixes
Most GH timing problems resolve with one of three adjustments. The correct fix depends on which variable is actually off.
Fix 1: Move Tesamorelin to daytime. If Tesamorelin is being injected at bedtime, move it to a fasted morning or early afternoon window. This is the single most common timing correction in GH research and often produces a measurable change in output within 1 to 2 weeks. If you are also tracking how the compound affects your sleep or how you feel day to day, the documented tesamorelin side effects are worth reviewing alongside the timing change so you can read what you are seeing.
Fix 2: Extend the fasted window. If a GLP-1 compound is running alongside the GH stack, extend the pre-injection fast from 2 to 3 hours to 4 to 5 hours post-meal. Also wait 60 to 90 minutes after injection before eating to let the pulse complete.
Fix 3: Sequence the stack correctly. If running both Tesamorelin and Ipamorelin, inject Tesamorelin first. Inject Ipamorelin 15 to 30 minutes later. Both injections fasted. Wait 60 to 90 minutes before eating. The boost from combining a GHRH and a GHRP is well documented, though the exact 15 to 30 minute spacing is more a practical convention than a settled clinical finding.
Retatrutide Timing: Should You Inject in the Morning or at Night?
Everything above is about growth hormone peptides, where timing is the whole game because the compound clears the body in a few hours. Retatrutide is the opposite case, and the difference is worth understanding if you are running both. Retatrutide is a once weekly compound with a long active life in the body, on the order of several days. That means the level in your system stays fairly steady from one day to the next, so the exact hour you inject does not swing the result the way it does with a short acting GH peptide. This is the same long active life that shapes how long retatrutide takes to start working.
Based on the data from the wider GLP-1 class, morning versus night makes little measurable difference to how well a long acting weekly compound performs, because a steady level does not rise and fall with the clock the way a short pulse does. Worth saying plainly: retatrutide is still being studied in clinical trials, so a lot of this is reasoned from the GLP-1 class and from its known long active life rather than from settled real world protocol.
So does it actually matter when you take retatrutide?
What matters more than the hour is consistency. Picking the same day each week keeps the level in your body stable, which is the entire point of a weekly compound. The one practical reason people pick a specific time is side effects, not results. Some researchers inject in the evening so that any nausea or low energy peaks while they are asleep. Others prefer the morning so they can eat normally through the day. Neither is more correct. It comes down to which pattern is easier to live with.
Can you inject retatrutide at night?
Yes. Because the compound stays active for days, a night injection and a morning injection reach nearly the same steady level over a full week. Night dosing is a common choice specifically because it can push the roughest part of the side effect curve into sleep. The thing to avoid is not night dosing itself, it is moving the injection all over the week, which makes it harder to read whether a change in how you feel is coming from the compound or from an inconsistent schedule.
Does retatrutide need a fasted window like GH peptides do?
No, and this is a common mix up when someone runs both at once. The fasted window matters for GH peptides because insulin from food blunts the growth hormone pulse in the moment. Retatrutide does not work through that short pulse, so it does not need the same empty stomach timing to do its job. The overlap only runs one direction. A GLP-1 compound slows how fast food leaves the stomach, which can stretch out the fasted window your GH peptide needs, and that is the interaction covered earlier in this guide.
Why do most researchers inject GH peptides at bedtime?
The common logic is that growth hormone naturally peaks during deep sleep, so bedtime injection seems intuitive. The problem is that most GH secretagogues like Tesamorelin have a short active window, roughly a couple of hours. By the time deep sleep arrives 60 to 90 minutes after falling asleep, the compound signal has already faded. Research suggests the timing assumption is based on a misread of how these compounds interact with the natural GH pulse.
Why does daytime injection produce a better result for most GH compounds?
Daytime injection creates a GH pulse your body does not naturally produce at that time of day. The mechanism points to this being an addition to your total GH output, not a replacement of the natural pulse. When the injection happens at bedtime, it competes with or arrives too early for the body's own peak. A daytime pulse on top of an intact natural pulse should give the researcher more total output over a full day.
Is CJC-1295 without DAC different from Tesamorelin when it comes to bedtime timing?
Yes. CJC-1295 without DAC has a shorter active window than Tesamorelin. When injected at bedtime, the pulse typically completes well before the natural GH peak occurs during deep sleep, which means the natural pulse arrives intact. Research suggests this makes CJC-1295 without DAC the one GH secretagogue where bedtime injection is a rational timing choice, though the comparison rests on practical protocol experience more than large head to head human trials. All other common secretagogues follow the daytime fasted rule.
Does fasting really matter before a GH peptide injection?
Research consistently shows that insulin present at injection time blunts the GH pulse significantly. Any meal within 2 to 3 hours of injection raises insulin and reduces the GH secretagogue response. Fasting before injection is not bro science. It is the primary timing variable that determines whether the compound produces its documented effect. Researchers who inject consistently without fasting still see results, but the output is not optimized.
What happens to the fasted window when a researcher is also running a GLP-1 compound?
GLP-1 compounds slow gastric emptying, meaning food that would normally clear the stomach in 3 to 4 hours may take 5 to 7 hours on an active GLP-1 protocol. Those hour figures are rough estimates, and for long acting GLP-1 compounds the slowdown often eases over the first weeks or months as the body adjusts. A standard 2 to 3 hour post-meal fasted window may not be sufficient early on. Research suggests extending the fasted window to 4 to 5 hours post-meal when running a GLP-1 compound alongside GH secretagogues.
How long should a researcher wait after injection before eating?
Most protocols use a 60 to 90 minute post-injection fasted window to allow the GH pulse to complete before somatostatin release from food intake blunts the signal. Ipamorelin specifically has an active window of roughly 2 hours, so waiting the full window before eating gives the pulse time to complete without interference.
Should you inject growth hormone peptides at night?
For most growth hormone peptides the answer is no. Compounds like Tesamorelin clear the body in a few hours, so a bedtime injection often fades before the natural deep sleep GH peak arrives. Research suggests a fasted daytime window works better for most GH secretagogues because it adds a second pulse without disrupting the natural one. CJC-1295 without DAC is the one common exception where bedtime timing is reasonable.
Is Tesamorelin better in the morning or at night?
Based on how short its active window is, Tesamorelin generally performs better with a fasted morning or early afternoon injection than at bedtime. Injected late at night, the signal tends to fade before the body's own GH peak during deep sleep. Morning also makes the fasted window easier to hold before the first meal of the day.
Should you take retatrutide in the morning or at night?
With retatrutide the time of day matters far less than it does for GH peptides. It is a once weekly compound that stays active for days, so the level in your body stays fairly steady no matter when you inject. Research on the wider GLP-1 class suggests morning versus night makes little difference to the result. The more useful habit is picking one consistent time and staying with it, since retatrutide is still being studied in trials and this leans on the GLP-1 class rather than settled human protocol.
Can you inject retatrutide at night?
Yes. Because retatrutide stays active for several days, a night dose and a morning dose reach nearly the same steady level across a week. Some researchers choose night specifically so that any nausea peaks while they sleep. Consistency from week to week matters more than the exact hour you inject.
This post covers the core logic. The membership goes further. The stack visualizer maps every compound in your protocol to its receptor targets and flags when two compounds are covering the same pathway, so you can see the overlap before it becomes a problem.
Members get the full stack visualizer, the deep dive PDF for this video, and a library of over 50 deep dive PDFs built from the YouTube video catalog, with one to two new deep dives added every week. The library grows every time a new video publishes.
For educational and research purposes only | Not medical advice | Not for human use guidance | Project Theo